The estimated Net Worth of Adora Ndu is at least $8.39 Tysiąc dollars as of 29 May 2024. Adora Ndu owns over 6,652 units of DBV Technologies stock worth over $8,387 and over the last 3 years Adora sold DBVT stock worth over $0.
Adora has made over 3 trades of the DBV Technologies stock since 2023, according to the Form 4 filled with the SEC. Most recently Adora exercised 6,652 units of DBVT stock worth $5,057 on 29 May 2024.
The largest trade Adora's ever made was exercising 6,652 units of DBV Technologies stock on 29 May 2024 worth over $5,057. On average, Adora trades about 2,143 units every 38 days since 2021. As of 29 May 2024 Adora still owns at least 11,033 units of DBV Technologies stock.
You can see the complete history of Adora Ndu stock trades at the bottom of the page.
Adora's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO, CA, 92130.
Over the last 3 years, insiders at DBV Technologies have traded over $13,911 worth of DBV Technologies stock and bought 45,919 units worth $58,352 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Timothy E Morris oraz Daniel B Soland. On average, DBV Technologies executives and independent directors trade stock every 91 days with the average trade being worth of $5,061. The most recent stock trade was executed by Pharis Mohideen on 29 July 2024, trading 1,785 units of DBVT stock currently worth $1,749.
dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and
DBV Technologies executives and other stock owners filed with the SEC include: